Encouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies

ISRCTN ISRCTN43532635
DOI https://doi.org/10.1186/ISRCTN43532635
Secondary identifying numbers N/A
Submission date
02/08/2004
Registration date
10/08/2004
Last edited
29/10/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Mr Malcolm Doupe
Scientific

Primary Health Care Research Unit
St Boniface Research Centre
Winnipeg, Manitoba
R2H 2A6
Canada

Email mdoupe@sbrc.ca

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)GP practice
Study typeQuality of life
Scientific titleEncouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies
Study acronymMAAUI
Study objectivesNot provided at time of registration
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedChronic pain
InterventionAll primary care physicians in Manitoba, Canada have been randomly assigned to a control group or an intervention study group. The educational intervention being evaluated consists of an audit and feedback mechanism combined with optional participation in a Continuing Medical Education interactive workshop. The primary outcome of the study is the change, from pre- to post- intervention, in physicians' appropriate prescribing of non-steroidal anti-inflammatory therapies for patients requiring chronic treatment. Three classes of non-steroidal anti-inflammatory therapies have been identified: a new class of non-steroidal anti-inflammatory agents known as coxib therapy, traditional non-steroidal anti-inflammatory drug (NSAID) monotherapy, and traditional NSAID therapy combined with gastro-protective agents. Appropriate prescribing is defined based on international clinical practice guidelines and the provincial drug reimbursement policy in Manitoba.
Intervention typeOther
Primary outcome measureNot provided at time of registration
Secondary outcome measuresNot provided at time of registration
Overall study start date01/11/2000
Completion date01/01/2004

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participantsNot provided at time of registration
Key inclusion criteriaAll primary care physicians in Manitoba, Canada
Key exclusion criteriaNot provided at time of registration
Date of first enrolment01/11/2000
Date of final enrolment01/01/2004

Locations

Countries of recruitment

  • Canada

Study participating centre

Primary Health Care Research Unit
Winnipeg, Manitoba
R2H 2A6
Canada

Sponsor information

Merck Frosst Canada and Co. (Canada)
Industry

C.P. 1005
Pointe-Claire-Dorval
Quebec
H9R 4P8
Canada

Email lorijean_manness@merck.com
ROR logo "ROR" https://ror.org/028979q34

Funders

Funder type

Industry

Merck Frosst Canada Ltd (Canada)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article Protocol 24/08/2004 Yes No